A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
MEK1/2 抑制剂比美替尼联合 MET 抑制剂克唑替尼治疗 RAS 突变型晚期结直肠癌患者的 Ia/b 期研究 (MErCuRIC)
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14068-1
Aroldi, Francesca; Elez, Elena; André, Thierry; Perkins, Geraldine; Prenen, Hans; Popovici, Vlad; Gallagher, Peter; Houlden, Jennifer; Collins, Linda; Roberts, Corran; Rolfo, Christian; Di Nicolantonio, Federica; Grayson, Margaret; Boyd, Ruth; Bettens, Karolien; Delfavero, Jurgen; Coyle, Victoria; Lawler, Mark; Khawaja, Hajrah; Laurent-Puig, Pierre; Salto-Tellez, Manuel; Maughan, Tim S; Tabernero, Josep; Adams, Richard; Jones, Robert; Hennessy, Bryan T; Bardelli, Alberto; Peeters, Marc; Middleton, Mark R; Wilson, Richard H; Van Schaeybroeck, Sandra